Baiyunshan announced the results of phase Ⅱ B clinical trial of therapeutic double plasmid HBV DNA vaccine project

On December 14, 2013, it was announced that the therapeutic double plasmid HBV DNA vaccine project invested by Guangzhou Baiyunshan Pharmaceutical Co., Ltd with a 60% interest and developed by the 458 Hospital of the people's Liberation Army started phase II B clinical trial in March 2011 A few days ago, the clinical trial has completed 72 weeks of comparative statistical results of data indicators of subjects, The results showed that there was no significant difference between the experimental group and the placebo group in the aspects of the incidence of viral breakthrough and drug resistance variation, the disappearance of HBeAg and serum conversion, the disappearance of HBsAg and serum conversion, the tolerance and safety; only in the aspect of the decrease and disappearance of HBV DNA at 64 weeks, the difference was statistically significant, among which 18.57% in the experimental group and 7.14% in the placebo group.